... follow-up computerized tomography (CT) imaging identified one lesion, present since the patient’s initial presentation, with a distinctly different response to treatment than other lesions. Biopsy results showed a distinct MPLC, an epidermal growth factor receptor ( EGFR )-positive adenocarcinoma...

... of many different cancer types, but its combination with other anti-cancer therapy is not well understood. We report a case of a 66-year-old woman who presented with triple-negative breast cancer, multifocal hormone receptor-positive breast cancer, primary epidermal growth factor receptor-mutated lung...

...Caio Teixeira Heleno; Seung Pyo D. Hong; Hyung-Gyo Cho; Min Jeong Kim; Yeonggyeong Park; Young Kwang Chae Cushing’s syndrome (CS), secondary to paraneoplastic syndrome, is more commonly seen in small cell lung cancer but never before reported in epidermal growth factor receptor-mutated...

...Boaz Wong; Sara Moore; Paul Wheatley-Price Epidermal growth factor receptor (EGFR) mutations are usually oncogenic drivers of lung tumor development and progression. While common sensitizing mutations respond well to targeted therapy, the relevance of germline EGFR mutations is less clear. We...

...Ali M. Alzahrani; Asma A. Alzahrani; Abdullah A. Alsharm The most common side effect for cancer patients using epidermal growth factor receptor inhibitors (EGFRI) is the development of an itchy papulopustular rash. In severe cases, the patients are forced to stop taking the medications, hence...

...Yuri Taniguchi; Hajime Horiuchi; Teppei Morikawa; Kazuhiro Usui There are various mechanisms underlying the resistance of EGFR-mutant lung adenocarcinoma to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). We herein report a case of pulmonary adenocarcinoma with EGFR...

... (Foundation ACT ® ) revealed an epidermal growth factor receptor exon 19 deletion, but due to the progression of the tumor and rapid deterioration in the patient’s performance status, a meaningful attempt at therapy directed to this recognized therapeutic target was not possible. This case provides important...

...Christina Brzezniak; Bruno A. Schmitz; Paul G. Peterson; Aiste Degesys; Bryan T. Oronsky; Jan J. Scicinski; Scott Z. Caroen; Corey A. Carter We present the case of a 49-year-old male with metastatic epidermal growth factor receptor (EGFR) mutation-positive adenocarcinoma of the lung that continues...

... lobectomy for lung adenocarcinoma (pT2aN0M0) 2 years ago was admitted for recurrence of lung cancer presenting as multiple brain metastases. An epidermal growth factor receptor mutation analysis of his lung cancer revealed a deletion of 15 nucleotides (E746-A750) in exon 19. After whole-brain radiotherapy...

...Nawazish A. Khan; Saied Mirshahidi; Hamid R. Mirshahidi The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein tyrosine kinase receptor. The small-molecule tyrosine kinase receptor inhibitors (TKIs) are in clinical use to treat non-small cell lung cancer with EGFR mutations...

... with an epidermal growth factor receptor (EGFR) mutation who underwent surgical resection after gefitinib treatment. The patient was a 66-year-old female with c-stage IIIA lung adenocarcinoma harboring an EGFR gene mutation; she was surgically treated after receiving gefitinib. The pathological examination revealed...

...Genovefa Polychronidou; Pavlos Papakotoulas The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are known to have greater efficacy in EGFR mutation-positive non-small cell lung cancer (NSCLC), although erlotinib also has activity in wild-type...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Sterile pustular rash Surrogate marker Acute generalized exanthematous pustulosis Epidermal growth factor receptor Erlotinib Case Rep Oncol 2012;5:253 259 DOI: 10.1159...